AMRI, HarkerBIO Ink Collaborative Agreement
News Jun 03, 2015
As part of the three-year agreement, AMRI gains access to HarkerBIO's uniquely differentiated high-resolution, structure-determination expertise and capabilities. HarkerBIO's customers will be able to access and benefit from AMRI's global capabilities, including their integrated drug discovery platforms and solutions.
"We are excited to be entering into this collaboration with HarkerBIO as we implement our new drug-discovery site in Buffalo, N.Y. Our new center in Buffalo offers customers leading-edge platforms and capabilities to translate early discoveries to the clinic via an integrated approach leveraging our expertise in chemistry, biology and pharmacology all located in a single site in the United States," said Michael A. Luther, Senior Vice President, Discovery and Development, AMRI.
Aimed at accelerating decision making and success in the translation from discovery to the clinic, the alliance with HarkerBIO is an early example of the types of partnerships AMRI is creating. AMRI's new discovery center is co-located on the Buffalo Niagara Medical Campus and is part of the larger commitment by the State of New York.
"We have a responsibility to our partners and customers to help drive the translation of innovation to the clinic to bridge the current gaps in discovery and development," Dr. Luther said, "Our strategy is to leverage and build creative and effective collaborations with on-campus and off-campus partners from global Pharma to academia including technology partners within this unique public-private environment."
"We are thrilled to be entering this collaborative agreement with AMRI, one of the most well-respected global drug discovery solution providers," says Paul Sargeant, CEO of HarkerBIO. "We are excited to bring HarkerBIO's unique structural biology services to AMRI's customers."
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.